Cosmos Health Inc. (COSM)
USD 0.45
(-2.91%)
USD 0.45
(-2.91%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -18.54 Million USD | -34.07% |
| 2022 | -13.83 Million USD | -73.71% |
| 2021 | -7.96 Million USD | -1070.0% |
| 2020 | 820.78 Thousand USD | 124.88% |
| 2019 | -3.29 Million USD | 63.59% |
| 2018 | -9.06 Million USD | -45.91% |
| 2017 | -6.2 Million USD | -933.24% |
| 2016 | -601 Thousand USD | 91.01% |
| 2015 | -6.68 Million USD | -210.64% |
| 2014 | 6.04 Million USD | 2351.29% |
| 2013 | 246.59 Thousand USD | 54296.04% |
| 2012 | -455.00 USD | 99.73% |
| 2011 | -169.24 Thousand USD | 95.53% |
| 2010 | -3.78 Million USD | -82252.8% |
| 2009 | -4600.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.86 Million USD | 86.43% |
| 2024 Q2 | -2.59 Million USD | -38.79% |
| 2023 Q3 | -3.34 Million USD | -241.22% |
| 2023 FY | -18.54 Million USD | -34.07% |
| 2023 Q1 | -459.86 Thousand USD | 95.75% |
| 2023 Q2 | -981.53 Thousand USD | -113.44% |
| 2023 Q4 | -13.75 Million USD | -310.61% |
| 2022 Q1 | 203.34 Thousand USD | 113.81% |
| 2022 Q3 | -1.97 Million USD | -58.93% |
| 2022 Q4 | -10.81 Million USD | -448.45% |
| 2022 FY | -13.83 Million USD | -73.71% |
| 2022 Q2 | -1.24 Million USD | -710.41% |
| 2021 Q2 | -2.37 Million USD | -9.44% |
| 2021 Q3 | -1.93 Million USD | 18.6% |
| 2021 Q4 | -1.47 Million USD | 23.98% |
| 2021 FY | -7.96 Million USD | -1070.0% |
| 2021 Q1 | -2.17 Million USD | -161.58% |
| 2020 Q1 | -483.31 Thousand USD | -627.69% |
| 2020 Q4 | -831.08 Thousand USD | -209.66% |
| 2020 Q3 | 757.86 Thousand USD | -44.97% |
| 2020 FY | 820.78 Thousand USD | 124.88% |
| 2020 Q2 | 1.37 Million USD | 384.97% |
| 2019 Q2 | -1.54 Million USD | -609.13% |
| 2019 Q4 | 91.59 Thousand USD | 105.61% |
| 2019 FY | -3.29 Million USD | 63.59% |
| 2019 Q1 | -217.17 Thousand USD | 97.83% |
| 2019 Q3 | -1.63 Million USD | -6.06% |
| 2018 Q2 | 782.38 Thousand USD | 125.6% |
| 2018 Q3 | 3.2 Million USD | 309.94% |
| 2018 Q4 | -9.99 Million USD | -411.62% |
| 2018 FY | -9.06 Million USD | -45.91% |
| 2018 Q1 | -3.05 Million USD | 2.54% |
| 2017 Q1 | -2.03 Million USD | -529.24% |
| 2017 FY | -6.2 Million USD | -933.24% |
| 2017 Q4 | -3.13 Million USD | -1482.26% |
| 2017 Q3 | -198.17 Thousand USD | 76.4% |
| 2017 Q2 | -839.61 Thousand USD | 58.72% |
| 2016 Q2 | -114.07 Thousand USD | -65.08% |
| 2016 Q4 | -323.2 Thousand USD | -241.61% |
| 2016 Q3 | -94.61 Thousand USD | 17.06% |
| 2016 FY | -601 Thousand USD | 91.01% |
| 2016 Q1 | -69.1 Thousand USD | 98.91% |
| 2015 Q2 | -132.62 Thousand USD | -22.06% |
| 2015 Q1 | -108.65 Thousand USD | 56.05% |
| 2015 FY | -6.68 Million USD | -210.64% |
| 2015 Q4 | -6.34 Million USD | -6221.59% |
| 2015 Q3 | -100.39 Thousand USD | 24.3% |
| 2014 Q2 | 928.28 Thousand USD | 51.13% |
| 2014 Q1 | 614.21 Thousand USD | -25.11% |
| 2014 Q3 | 4.74 Million USD | 411.64% |
| 2014 Q4 | -247.24 Thousand USD | -105.21% |
| 2014 FY | 6.04 Million USD | 2351.29% |
| 2013 Q2 | -43.84 Thousand USD | 24.47% |
| 2013 FY | 246.59 Thousand USD | 54296.04% |
| 2013 Q1 | -58.04 Thousand USD | 49.5% |
| 2013 Q3 | -79.83 Thousand USD | -82.1% |
| 2013 Q4 | 820.14 Thousand USD | 1127.31% |
| 2012 Q2 | -59.72 Thousand USD | -9.46% |
| 2012 Q1 | -54.56 Thousand USD | 2.41% |
| 2012 Q4 | -114.93 Thousand USD | 10.02% |
| 2012 Q3 | -127.72 Thousand USD | -113.85% |
| 2012 FY | -455.00 USD | 99.73% |
| 2011 Q3 | -160.38 Thousand USD | -161.17% |
| 2011 Q2 | -61.41 Thousand USD | 29.69% |
| 2011 Q4 | -55.91 Thousand USD | 65.14% |
| 2011 Q1 | -87.34 Thousand USD | -646.45% |
| 2011 FY | -169.24 Thousand USD | 95.53% |
| 2010 Q1 | -21.32 Thousand USD | -162.13% |
| 2010 FY | -3.78 Million USD | -82252.8% |
| 2010 Q2 | -3.71 Million USD | -17342.85% |
| 2010 Q3 | -8783.00 USD | 99.76% |
| 2010 Q4 | -11.7 Thousand USD | -33.23% |
| 2009 FY | -4600.00 USD | 0.0% |
| 2009 Q4 | -8135.00 USD | 79.28% |
| 2009 Q3 | -39.25 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 198.741% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -135.612% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 138.506% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 7.552% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 91.138% |
| Cronos Group Inc. | -73.96 Million USD | 74.93% |
| Incannex Healthcare Limited | -18.45 Million USD | -0.453% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 56.059% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 254.355% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -331.04% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -311.506% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -311.506% |
| SCYNEXIS, Inc. | 67.04 Million USD | 127.659% |
| Safety Shot Inc | -15.08 Million USD | -22.937% |
| Theratechnologies Inc. | -23.95 Million USD | 22.6% |
| Alpha Teknova, Inc. | -36.78 Million USD | 49.585% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -200.868% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 144.197% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -283.509% |
| Dynavax Technologies Corporation | -6.38 Million USD | -190.228% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 98.15% |
| Radius Health, Inc. | -25.79 Million USD | 28.104% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -498.434% |
| Alvotech | -551.73 Million USD | 96.639% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 86.724% |
| SIGA Technologies, Inc. | 68.06 Million USD | 127.241% |
| Shineco, Inc. | -22.44 Million USD | 17.401% |
| Silver Spike Investment Corp. | 7.34 Million USD | 352.621% |
| Journey Medical Corporation | -3.85 Million USD | -381.252% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -127.15% |
| Embecta Corp. | 70.4 Million USD | 126.339% |
| Harrow Health, Inc. | -24.41 Million USD | 24.04% |
| Procaps Group, S.A. | 42.54 Million USD | 143.589% |
| Biofrontera Inc. | -20.13 Million USD | 7.89% |
| DURECT Corporation | -27.62 Million USD | 32.875% |
| PainReform Ltd. | -9.34 Million USD | -98.444% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1509.016% |
| OptiNose, Inc. | -35.48 Million USD | 47.742% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 177.532% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 474.978% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -195.297% |
| ProPhase Labs, Inc. | -16.78 Million USD | -10.491% |
| Phibro Animal Health Corporation | 2.41 Million USD | 867.494% |
| Procaps Group S.A. | 42.54 Million USD | 143.589% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -80.411% |
| Viatris Inc. | 54.7 Million USD | 133.899% |
| Rockwell Medical, Inc. | -8.43 Million USD | -119.726% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -17.033% |
| Tilray Brands, Inc. | -244.98 Million USD | 92.431% |
| PetIQ, Inc. | 2.13 Million USD | 970.139% |
| Talphera, Inc. | -18.39 Million USD | -0.792% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 107.426% |
| Alimera Sciences, Inc. | -20.13 Million USD | 7.895% |
| Assertio Holdings, Inc. | -331.94 Million USD | 94.414% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -181.259% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 88.431% |
| Hempacco Co., Inc. | -13.12 Million USD | -41.266% |
| Alvotech | -551.73 Million USD | 96.639% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 105.676% |
| Kamada Ltd. | 8.28 Million USD | 323.837% |
| Currenc Group, Inc. | -15.3 Million USD | -21.142% |
| Indivior PLC | 2 Million USD | 1027.133% |
| Evoke Pharma, Inc. | -7.79 Million USD | -137.961% |
| Flora Growth Corp. | -57.03 Million USD | 67.49% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 7.552% |
| Evolus, Inc. | -61.68 Million USD | 69.94% |
| HUTCHMED (China) Limited | 100.78 Million USD | 118.399% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 113.481% |
| Akanda Corp. | -32.27 Million USD | 42.548% |